iOnctura Develops Next-Generation PI3K-Delta Inhibitors For Cancer
New Biotech Combining Insights In Fibrosis And Cancer
Emerging Company Profile: Switzerland’s iOnctura is working on PI3K-delta inhibitors and autotaxin inhibitors that have potential in solid tumors and cancer-associated fibrosis.
